Scarica l'app Stockscreener
0.6385
5.87%
-0.0399
Precedente Chiudi:
$0.6784
Aprire:
$0.678
Volume 24 ore:
152.54K
Relative Volume:
0.94
Capitalizzazione di mercato:
$10.93M
Reddito:
$4.03M
Utile/perdita netta:
$24.32M
Rapporto P/E:
-0.1485
EPS:
-4.3008
Flusso di cassa netto:
$-45.76M
1 W Prestazione:
+1.06%
1M Prestazione:
-11.70%
6M Prestazione:
-16.49%
1 anno Prestazione:
-42.48%
Intervallo 1D:
$0.6352
$0.678
Intervallo di 1 settimana:
$0.63
$0.69
Portata 52W:
$0.55
$1.90
Pavmed Inc Stock (PAVM) Company Profile
Nome
Pavmed Inc
Settore
Industria
Telefono
(212) 949-4319
Indirizzo
360 MADISON AVENUE, NEW YORK, NY
Confronta PAVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.6385 | 10.93M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
135.62 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
99.74 | 151.04B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
377.30 | 146.71B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.27 | 112.09B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.15 | 45.47B | 5.54B | 4.18B | 623.10M | 7.00 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Iniziato | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Iniziato | Maxim Group | Buy |
Pavmed Inc Borsa (PAVM) Ultime notizie
PAVmed (NASDAQ:PAVM) Given New $19.00 Price Target at Ascendiant Capital Markets - Defense World
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - MSN
PAVM: Ascendiant Capital Maintains Buy Rating but Lowers Price Target | PAVM Stock News - GuruFocus
PAVmed subsidiary Veris Health partners with Ohio State University cancer center - Yahoo Finance
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnersh - GuruFocus
PAVM Subsidiary Veris Health Partners with OSUCCC -- James for Cancer Care Innovations | PAVM Stock News - GuruFocus
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer CenterJames Cancer Hospital and Solove Research Institute | PAVM Sto - GuruFocus
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com UK
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
PAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Call Transcript - Insider Monkey
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification - Yahoo Finance
Pavmed Inc. Reports Turnaround with Strong Q1 Earnings - TipRanks
PAVmed Q1 2025 slides: net income soars amid strategic restructuring By Investing.com - Investing.com India
PAVmed Q1 2025 slides: net income soars amid strategic restructuring - Investing.com
Earnings call transcript: PAVmed’s Q1 2025 sees strong net income and strategic shifts - Investing.com Nigeria
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Reports Q1 2025 Financial Results and Updates - TipRanks
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
PAVmed Q1 Earnings: $40M Cash Runway Powers Multi-Subsidiary Growth and Biopharma Entry Plans - Stock Titan
PAVmed (PAVM) Q1 Earnings Beat with Improved EPS and Revenue - GuruFocus
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Provides Business Update and Reports First Qua - GuruFocus
Lucid Diagnostics Reports Q1 2025 Financial Results - TipRanks
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results - StreetInsider
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - Finansavisen
Transcript : Lucid Diagnostics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PAVmed (PAVM) to Release Quarterly Earnings on Thursday - Defense World
PAVmed to Hold a Business Update Conference Call and Webcast on - GuruFocus
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 - The Victoria Advocate
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 | PAVM Stock News - GuruFocus
PAVmed Sets Key Q1 2025 Earnings Call: MedTech Growth Strategy and Financial Results Coming May 15 - Stock Titan
Lucid Diagnostics to Reveal Q1 2025 Financial Results and Growth StrategyKey Details for Investors - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
PAVmed switches to new accounting firm post-acquisition - Investing.com Australia
PAVmed switches to new accounting firm post-acquisition By Investing.com - Investing.com South Africa
PAVmed, Lucid post encouraging results from EsoGuard study (LUCD:NASDAQ) - Seeking Alpha
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - StreetInsider
Breakthrough: NCI Study Validates EsoGuard's Perfect Accuracy for Early Cancer Detection$60B Market Impact - Stock Titan
Ascendiant Capital Markets Forecasts Strong Price Appreciation for PAVmed (NASDAQ:PAVM) Stock - The AM Reporter
PAVmed (NASDAQ:PAVM) Price Target Raised to $19.50 at Ascendiant Capital Markets - Defense World
PAVmed Files Prospectus Relates To Potential Offer, Sale From Time To Time Of 3.3 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - ADVFN
Pavmed Inc Azioni (PAVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.68%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):